Skip to main content

Danaher Corporation company profile

  • DHR · NYSE
  • Instruments
  • Life Sciences Tools & Services
  • S&P 500
$229.91−1.33%Close 16 Nov 2026 · Market value $159.0B

About Danaher Corporation

Danaher Corporation is a science and technology company with three operating segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment provides equipment, consumables, software and services used in the research, development, manufacture and delivery of biological medicines, through its bioprocessing and discovery and medical businesses. The Life Sciences segment offers instruments, consumables, services and software used to study cells, proteins and nucleic acids, along with filtration products for liquids and gases. The Diagnostics segment supplies clinical instruments, consumables, software and services used by hospitals, physicians' offices and reference laboratories to diagnose disease. Customers include pharmaceutical and biotechnology companies, research institutions, laboratories and healthcare providers. Facilities for research, manufacturing, sales, distribution and service are located in approximately 50 countries.

A summary of the business section of the company's latest annual report, filed 24 Feb 2026.

Company facts

TickerDHR · NYSE
SectorInstruments
IndustryLife Sciences Tools & Services
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK313616
Latest annual report10-K, filed 24 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
Matthew R. McGrewExecutive Vice President231K · < 1%Option exercise, 9 Nov 2026
Christopher P. RileyExecutive Vice President117K · < 1%Grant or award, 4 Aug 2026
Alan G. SpoonDirector106K · < 1%Grant or award, 15 May 2026
Julie Sawyer MontgomeryExecutive Vice President98.8K · < 1%Grant or award, 1 Mar 2026
John T. SchwietersDirector61.8K · < 1%Shares withheld for tax, 15 Jul 2025
Jose-Carlos Gutierrez-RamosSVP, Chief Science Officer60.4K · < 1%Grant or award, 4 Aug 2026
Elias A. Zerhouni, MDDirector37.3K · < 1%Shares withheld for tax, 15 Jul 2026
Raymond C. Stevens, Ph.D.Director15.2K · < 1%Grant or award, 15 May 2026
A. Shane SandersDirector9.0K · < 1%Grant or award, 15 May 2026
Milosevich Gregory MExecutive Vice President—Open-market sale, 9 Nov 2026
Bouda ChristopherVP, Chief Accounting Officer—Option exercise, 28 Oct 2026
RALES MITCHELL PChairman of Exec. Committee · Director—Disposition to the issuer, 9 Oct 2026
RALES STEVEN MChairman · Director—Disposition to the issuer, 9 Oct 2026
Blair RainerPresident & CEO · Director—Open-market sale, 21 Aug 2026
FILLER LINDADirector—Shares withheld for tax, 15 Jul 2026
Couchara GeorgeannSVP, Human Resources—Shares withheld for tax, 15 May 2026
List TeriDirector—Grant or award, 15 May 2026
Dewan FerozDirector—Grant or award, 15 May 2026
Lamanna Charles WDirector—Grant or award, 15 May 2026
Leiken JonathanSVP-Chief Legal Officer—Grant or award, 1 Mar 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

DHR in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.